Cervical Cancer Prevention: An Update on New Screening and Risk-Based Management Guidelines

Cervical cancer prevention has changed significantly in recent years with less frequent screening and with the approval of HPV primary screening every 5 years, with a reflex Pap done only if the HPV test is positive. Additionally, cotesting with Pap and HPV every 5 years or Pap alone every 3 years remains an option. This session will review the appropriate use of Pap testing, the rationale for HPV testing along with the Pap (co-testing) in women 30 and older and the use of HPV testing as a primary screen (stand-alone test) in women 25 and older by two of the FDA approved HPV tests. There will be a discussion of the American Cancer Society Guidelines for screening and a review of the 2019 ASCCP Risk-Based Management Consensus Guidelines for management of abnormal screening and subsequent follow-up with case studies. These guidelines are a shift from results-based to risk-based management relative to the risk of an existing CIN 3 (pre-cancer).

 *Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.0 Contact Hours; 0 are Pharmacology
Expiration Date: December 31, 2025

$27.50

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-Describe the role of persistent oncogenic HPV in the development of pre-cancer and cancer of the cervix
-List two different uses of HPV testing in cervical cancer
-Discuss cervical cancer screening guidelines from ASCCP, USPSTF, ACP and the new American Cancer Society guidelines.
-Discuss the 2019 Risk-Based Management Consensus Guidelines

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 0 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Nancy Berman, MSN, ANP-BC, MSCP, FAANP has disclosed:

Astellas: Self Advisory Board, Speakers Bureau Non-hormonal treatment of vasomotor symptoms Veozah
Bayer: Spouse Consulting Contraception Essure
Hologic: Spouse Consulting Fibroids Accessa
Organon Consulting Contraception Nexplanon

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.